About Me
Cardiologist
Data Scientist
Banerjee Lab
Projects
STIMULATE-ICP
The DISC Study
Publications
COVID-19
Blog
Contact
Educator
News
Publications
Publicatons
Publications
AUG
12
Healthcare utilisation and cost among individuals with Long COVID in England and Wales: potential value of specialised post-COVID services
By:
Ashkan Dashtban
on
AUG
12
CONCLUSIONS: LC is associated with sustained increases in healthcare utilisation and costs in England and Wales. Our findings suggest that system-level service design may influence healthcare use and costs following COVID-19, warranting further evaluation of post-viral care models.
Read more >>
JUL
28
Integrated care pathway in individuals with Long COVID: STIMULATE-ICP, a cluster-randomized, phase 3 trial
By:
STIMULATE-ICP Consortium
on
JUL
28
Combining multidisciplinary care plans into integrated care pathways (ICPs) is scalable, generalizable and effective for several long-term conditions, but not evaluated in Long COVID (LC). Our phase 3, cluster-randomized, multicenter clinical trial investigated the effectiveness of ICP interventions for LC. Recruitment of adults ≥18 years with LC was conducted in 6 National Health Service LC clinics in England with specialist ICPs. The intervention arms were (i) multi-organ magnetic resonance...
Read more >>
JUL
11
Scalable risk stratification of undiagnosed heart failure using routine health data and its association with imaging phenotypes and outcomes
By:
Yoko M Nakao
on
JUL
11
Late diagnosis of Heart failure (HF) is associated with worse outcomes. We aimed to develop a scalable tool to identify those at high risk of undiagnosed HF using routine electronic health records (EHR). We developed and internally validated a logistic regression (FIND-HF) model for incident HF diagnosis within one year in United Kingdom primary care EHRs (CPRD-Aurum, n=3 520 186), with good prediction performance (area under the receiver operating characteristic curve (AUC) 0.79), equal to more...
Read more >>
JUL
08
Efficacy and safety of rivaroxaban, colchicine, and famotidine-loratadine with specialist supportive clinical care for fatigue in patients with post-COVID-19 condition in the UK: a multisite, open-label, randomised controlled trial
By:
STIMULATE-ICP consortium
on
JUL
08
BACKGROUND: Post-acute sequelae of COVID-19 or post-COVID-19 condition (also known as long COVID) affects 1-5% of adults globally, most commonly with fatigue, and no evidence-based therapies are available. We aimed to evaluate the efficacy of repurposed medications in fatigue management in adults with long COVID.
Read more >>
JUL
06
AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026)
By:
Mary Norine Walsh
on
JUL
06
Heart failure (HF) remains a pressing health concern, with rising prevalence globally. Subjectivity and ambiguity in the definition of HF and its antecedent stages have limited research, global surveillance, and prevention programs. To address this, several cardiac societies and foundations convened to standardize the definition of HF in 2021 and designated stage B or pre-HF to identify individuals at risk of developing HF. In subsequent years, substantial progress and changes have been made in...
Read more >>
JUN
29
AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026)
By:
Mary Norine Walsh
on
JUN
29
Heart failure (HF) remains a pressing health concern, with rising prevalence globally. Subjectivity and ambiguity in the definition of HF and its antecedent stages have limited research, global surveillance, and prevention programs. To address this, several cardiac societies and foundations convened to standardize the definition of HF in 2021 and designated stage B or pre-HF to identify individuals at risk of developing HF. In subsequent years, substantial progress and changes have been made in...
Read more >>
JUN
29
AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026)
By:
Mary Norine Walsh
on
JUN
29
Heart failure (HF) remains a pressing health concern, with rising prevalence globally. Subjectivity and ambiguity in the definition of HF and its antecedent stages have limited research, global surveillance, and prevention programs. To address this, several cardiac societies and foundations convened to standardize the definition of HF in 2021 and designated stage B or pre-HF to identify individuals at risk of developing HF. In subsequent years, substantial progress and changes have been made in...
Read more >>
JUN
29
AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026)
By:
Mary Norine Walsh
on
JUN
29
Heart failure (HF) remains a pressing health concern, with rising prevalence globally. Subjectivity and ambiguity in the definition of HF and its antecedent stages have limited research, global surveillance, and prevention programs. To address this, several cardiac societies and foundations convened to standardize the definition of HF in 2021 and designated stage B or pre-HF to identify individuals at risk of developing HF. In subsequent years, substantial progress and changes have been made in...
Read more >>
JUN
15
The impact of post-acute sequelae of COVID-19 on cardiac function and structure: A systematic review and a hybrid individual participant data meta-analysis
By:
Binyam Tariku Seboka
on
JUN
15
CONCLUSION: This review indicates that PASC is associated with modest, subclinical alterations in cardiac function. These alterations appear more pronounced in older adults and those with cardiometabolic comorbidities, highlighting the potential value of risk-stratified cardiovascular surveillance in individuals with PASC. The long-term clinical relevance of these changes remains unclear and warrants further study.
Read more >>
JUN
10
Assessing Europe's policy readiness to confront the MASLD/MASH public health threat
By:
Jeffrey V Lazarus
on
JUN
10
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a public health threat in Europe. With an estimated 30.4% prevalence among the adult population in the European Union and United Kingdom, it is the most common chronic liver disease and is closely linked to obesity and type 2 diabetes, which can be considered as indicator conditions. Despite the scale of the burden, the spectrum of MASLD, including its advanced form, metabolic dysfunction-associated steatohepatitis (MASH), is...
Read more >>
More Posts
Create your business website with
Website Builder.
Share by: